EUVIMEDEUVIMED entdecken
Crossref

Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody–drug conjugates by specific hinge fragmentation-liquid chromatography

Yun Yang, Jaymin M Patel, Rong-Sheng Yang, Fengfei Ma, Xiangfeng Niu, Yixiao Zhang, Thomas Niedringhaus, Mohammad Al-Sayah, Xiaoyu Yang

Analytical and Bioanalytical Chemistry · 2025

DOI: 10.1007/s00216-024-05707-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical and Bioanalytical Chemistry, 2025. Verfasst von Yun Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Analytical Research, Merck & Co., Inc, 213 E Grand Ave, South San Francisco, CA, 94080, USA. Hauptthemen laut MEDLINE: Cysteine, Immunoconjugates, Antibodies, Monoclonal, Immunoglobulin Fc Fragments. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The site-specific antibody-drug conjugates (ADCs), particularly those utilizing the engineered cysteine in Fc fragments of mAbs (THIOMAB™ antibodies), have emerged as a novel class of biotherapeutics for cancer treatment. The engineered cysteine residues in these antibodies are capped by cysteine or glutathione through a disulfide bond. Prior to conjugation with linker-payloads, these caps need to be removed through a reduction process. However, monitoring the efficiency of the decapping process has been challenging due to the lack of effective analytical methods. Intact reversed-phase liquid chromatography-mass spectrometry and hydrophobic interaction chromatography methods failed to separate decapped and capped intact THIOMAB™ mAbs in our study. Instead the fragmentation of mAbs provided a novel strategy to analyze the decapping effiency. After cleavage using a hinge specific enzyme, the generated Fc fragments with and without cysteine and/or glutathione caps displayed different hydrophobicity and were well separated by RPLC, allowing quantitative determination of the decapping efficiency. Enzymes that cleave both above and below the hinge disulfide bonds were tested. The use of FabALATICA can determine percentages of molecules with 0, 1, and 2 cysteine and/or glutathione caps, respectively, regardless of whether the antibody contains the hinge LALA mutations. On the other hand, FabRICATOR enzyme can only be utilized for antibodies without LALA mutations for the overall decapping percentage and cannot be used to estimate intact antibody each with 0, 1, and 2 caps. Therefore, FabALACTICA cleavage followed by RPLC provides a wider application of monitoring the decapping efficiency of all antibodies with the engineered cysteine in Fc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CysteineImmunoconjugatesAntibodies, MonoclonalImmunoglobulin Fc FragmentsHumansChromatography, LiquidChromatography, Reverse-PhaseHydrophobic and Hydrophilic InteractionsProtein EngineeringMass Spectrometry

Stichwörter der Autor:innen

AntibodyAntibody–drug conjugates (ADCs)Decapping efficiencyEngineered cysteineFc fragmentSpecific hinge fragmentationThiomabsmAbs

Substanzen

CysteineImmunoconjugatesAntibodies, MonoclonalImmunoglobulin Fc Fragments

Autor:innen und Institutionen

  • Discovery Analytical Research, Merck & Co., Inc, 213 E Grand Ave, South San Francisco, CA, 94080, USA.
  • Biologics Analytical Research and Development (BARD), Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ, 07065, USA.
  • Analytical Research and Development, Merck & Co., Inc, 126 E. Lincoln Avenue, Rahway, NJ, 07065, USA.
  • Bioprocess Research & Development, Merck & Co., Inc, 126 E. Lincoln Avenue, Rahway, NJ, 07065, USA.
  • Discovery Analytical Research, Merck & Co., Inc, 213 E Grand Ave, South San Francisco, CA, 94080, USA. xiaoyu.yang@merck.com.
  • Biologics Analytical Research and Development (BARD), Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, NJ, 07065, USA. xiaoyu.yang@merck.com.

Zitieren

APA

Yang, Y., Patel, J. M., Yang, R. S., Ma, F., Niu, X., Zhang, Y., Niedringhaus, T., Al-Sayah, M., & Yang, X. (2025). Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody–drug conjugates by specific hinge fragmentation-liquid chromatography. Analytical and Bioanalytical Chemistry. https://doi.org/10.1007/s00216-024-05707-w

Vancouver

Yang Y, Patel JM, Yang RS, Ma F, Niu X, Zhang Y, et al. Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody–drug conjugates by specific hinge fragmentation-liquid chromatography. Analytical and Bioanalytical Chemistry. 2025. doi:10.1007/s00216-024-05707-w

BibTeX
@article{Yang2025,
  author = {Yang, Yun and Patel, Jaymin M and Yang, Rong-Sheng and Ma, Fengfei and Niu, Xiangfeng and Zhang, Yixiao and Niedringhaus, Thomas and Al-Sayah, Mohammad and Yang, Xiaoyu},
  title = {Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody–drug conjugates by specific hinge fragmentation-liquid chromatography},
  journal = {Analytical and Bioanalytical Chemistry},
  year = {2025},
  doi = {10.1007/s00216-024-05707-w}
}
Kostenlos starten →